Use of sugammadex on burn patients: descriptive study.

Abstract

OBJECTIVES:

A burn patient is a challenge for any anesthesiologist, undergoing several surgeries during admission, and requiring general anesthesia and muscle relaxation most of the times. The victim may have respiratory system impairment and a response to muscle relaxants that differs from the healthy patient, thus proper monitoring and reversal is crucial. We analyzed sugammadex effectiveness and safety in this population.

MATERIALS AND METHODS:

It was a prospectively descriptive study, including 4 patients, and all of them were considered major burn patients, who underwent escharotomy with general anesthesia and neuromuscular relaxation. The main variable was the time for recovery of a TOF higher than 0.9 after the administration of sugammadex before extubation.

RESULTS:

Mean time of recovery from a TOF ratio higher than 0.9 following the administration of Sugammadex was of 4.95min 95% CI (3.25-6.64, p=.53).

CONCLUSIONS:

The reversion of neuromuscular relaxation with sugammadex appears to be effective and safe in the burn patient. More analytical, comparative studies of larger populations would be necessary to confirm these data.

• Authors: Eduardo Rodríguez Sánchez M, Concepción Martínez Torres, Pablo Herrera Calo, Ignacio Jiménez
• Journal: Brazilian journal of anesthesiology (Elsevier) (Braz J Anesthesiol) 2015 Jul-Aug Vol. 65 Issue 4 Pg. 240-3 ISSN: 2352-2291 [Electronic] Brazil
• PMID: 26123141 (Publication Type: Journal Article)
• Copyright: Copyright © 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.

Chemical References

• Neuromuscular Nondepolarizing Agents
• gamma-Cyclodextrins
• Sugammadex

Topics

• Aged
• Anesthesia, General (methods)
• Burns (physiopathology, surgery)
• Female
• Humans
• Male
• Neuromuscular Monitoring (methods)
• Neuromuscular Nondepolarizing Agents (administration & dosage)
• Prospective Studies
• Sugammadex
• gamma-Cyclodextrins (administration & dosage, adverse effects)